| Literature DB >> 21628484 |
Iris De Schutter1, Elke De Wachter, Françoise Crokaert, Jan Verhaegen, Oriane Soetens, Denis Piérard, Anne Malfroot.
Abstract
BACKGROUND: Precise etiologic diagnosis in pediatric community-acquired pneumonia (CAP) remains challenging.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21628484 PMCID: PMC7107807 DOI: 10.1093/cid/cir235
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 9.079
Overview of Microbiological Investigations Performed on Samples and Diagnostic Criteria
| Specimen | Infectious agent | Assay | Diagnostic criteria |
| BAL fluid | Aerobic bacteria | Culture | ≥104 cfu/mL (cut-off value) |
| Viruses | Culture | Growth | |
| Respiratory viruses | Multiplex PCR | Positive | |
| Atypical | Multiplex PCR | Positive | |
| NPA | Viruses | Culture | Growth |
| Respiratory viruses | Multiplex PCR | Positive | |
| Atypical | Multiplex PCR | Positive | |
| Blood | Aerobic bacteria | Culture | Growth |
| Viruses | Complement fixation | Acute titer ≥120 | |
|
| Complement fixation | Acute titer ≥320 | |
| Pleural fluid | Bacteria | Culture | Growth |
NOTE. BAL, bronchoalveolar lavage; cfu, colony-forming units; NPA, nasopharyngeal aspirate; PCR, polymerase chain reaction.
Influenzavirus A and B; parainfluenza virus types 1, 2, 3; respiratory syncytial virus; human metapneumovirus subtypes A and B; coronavirus 229E and OC43.
M. pneumoniae and Chlamydophila pneumoniae.
Serological testing for influenzavirus A and B, adenovirus, picornavirus, and respiratory syncytial virus.
Reverse titer.
Patient Characteristics and Antibiotic Use in the 48 h Before Flexible Bronchoscopy With Bronchoalveolar Lavage
| Age, months | Sex, % | Receipt of antibiotic ≤48h before flexible bronchoscopy with bronchoalveolar lavage, no. (%) of patients | |||||
| Group | No. of patients | Median | Range | Female | Male | Yes | No |
| NR-CAP | 127 | 33.1 | 1.0–171.6 | 49 | 51 | 98 (77) | 29 (23) |
| Lobar pneumonia | 53 | 37.1 | 5.0–171.6 | 47 | 53 | 46 (87) | 7 (13) |
| Bronchopneumonia | 64 | 29.1 | 1.0–136.5 | 50 | 50 | 42 (66) | 22 (34) |
| Pneumonia and pleural effusion | 10 | 47.7 | 3.0–93.3 | 50 | 50 | 10 (100) | 0 (0) |
| Rec-CAP | 123 | 33.1 | 4.0–170.6 | 43 | 57 | 29 (24) | 86 (70) |
NOTE. NR-CAP, nonresponding community-acquired pneumonia; Rec-CAP, recurrent community-acquired pneumonia.
Antibiotic use unknown in 8 children.
Distribution of Pathogens Detected in Both Groups
| No. (%) of patients | |||
| Variable | NR-CAP ( | Rec-CAP ( |
|
| Patients with ≥1 pathogen detected | 95 (74.8) | 95 (77.2) | NS |
| Exclusively aerobic bacteria | 26 (20.5) | 47 (38.2) | .003 |
| Exclusively viruses | 21 (16.5) | 9 (7.3) | .04 |
| Exclusively atypical microorganisms | 24 (18.9) | 4 (3.2) | <.001 |
| Mixed infection | 24 (18.9) | 37 (30.1) | NS |
| Patients with no pathogen detected | 32 (25.1) | 28 (22.8) | NS |
NOTE. NR-CAP, nonresponding community-acquired pneumonia; NS, not significant; Rec-CAP, recurrent community-acquired pneumonia.
By χ2 test.
Overview of Pathogens Detected
| Pathogen | NR-CAP ( | Rec-CAP ( |
| ||||
| Mono culture | Coinfection | Total, no. (%) of patients | Mono culture | Coinfection | Total, no. (%) of patients | ||
| Aerobic bacteria | 33 | 14 | 47 (37.0) | 54 | 27 | 81 (65.8) | <.001 |
| | 27 | 6 | 33 (26.0) | 39 | 24 | 63 (51.2) | <.001 |
| | 2 | 9 | 11 (8.7) | 9 | 17 | 26 (21.1) | .009 |
| | 2 | 6 | 8 (6.3) | 3 | 6 | 9 (7.3) | NS |
| | 2 | 3 | 5 (3.9) | 0 | 5 | 5 (4.1) | NS |
| | 0 | 1 | 1 (0.8) | 1 | 1 | 2 (1.6) | NS |
| | 0 | 2 | 2 (1.6) | 1 | 0 | 1 (0.8) | NS |
| | 0 | 0 | 0 (0) | 0 | 1 | 1 (0.8) | NS |
| β-hemolytic streptococci | 0 | 0 | 0 (0) | 0 | 2 | 2 (1.6) | NS |
| | 0 | 2 | 2 (1.6) | 1 | 1 | 2 (1.6) | NS |
| Viruses | 30 | 11 | 41 (32.3) | 30 | 5 | 35 (28.5) | NS |
| Respiratory syncytial virus | 8 | 7 | 15 (11.8) | 6 | 1 | 7 (5.7) | NS |
| Parainfluenzaviruses | 5 | 1 | 6 (4.7) | 8 | 1 | 9 (7.3) | NS |
| Influenzaviruses | 5 | 3 | 8 (6.3) | 2 | 2 | 4 (3.3) | NS |
| Adenovirus | 5 | 1 | 6 (4.7) | 1 | 3 | 4 (3.3) | NS |
| Human metapneumovirus | 3 | 1 | 4 (3.1) | 4 | 1 | 5 (4.1) | NS |
| Picornavirus | 2 | 4 | 6 (4.7) | 1 | 0 | 1 (0.8) | NS |
| Coronaviruses | 1 | 3 | 4 (3.1) | 2 | 0 | 2 (1.6) | NS |
| Cytomegalovirus | 1 | 1 | 2 (1.6) | 2 | 2 | 4 (3.3) | NS |
| Enterovirus (not polio) | 0 | 0 | 0 (0) | 4 | 1 | 5 (4.1) | NS |
| Rhinovirus | 0 | 1 | 1 (0.8) | 0 | 0 | 0 (0) | NS |
| Atypical microorganisms | 37 | 19 | .015 | ||||
| | 37/106 tested (34.9) | 16/83 tested (19.3) | .03 | ||||
| | 0/58 tested (0) | 3/54 tested (5.6) | NS | ||||
NOTE. NR-CAP, nonresponding community-acquired pneumonia; Rec-CAP, recurrent community-acquired pneumonia; coinfection: cases in which at least 2 infective agents of the same microbiological group were isolated; NS, not significant.
n = 122 for viruses.
By χ2 test.
Distribution of Pathogens in Mixed Infections
| Pathogen(s) | NR-CAP | Rec-CAP | ||
| Mono culture | coinfection | Mono culture | coinfection | |
| Bacteria and virus | 8 | 3 | 16 | 7 |
| | 6 | 1 | 10 | 4 |
| Adenovirus | 2 | … | … | … |
| RSV | 1 | … | 2 | … |
| Influenzavirus A | 1 | … | … | 1 |
| Parainfluenzavirus | 2 | … | 4 | 1 |
| hMPV | … | 1 | 1 | … |
| Cytomegalovirus | … | … | 1 | … |
| Parainfluenzavirus/adenovirus | … | … | 1 | … |
| Enterovirus/influenzavirus B | … | … | 1 | … |
| hMPV/adenovirus/influenzavirus B | … | … | … | 1 |
| Adenovirus/CMV | … | … | … | 1 |
| | … | 1 | 1 | 1 |
| hMPV | … | 1 | 1 | … |
| coronavirus OC43 | … | … | … | 1 |
|
| 1 | 2 | 2 | 3 |
| RSV | 1 | … | … | … |
| Coronavirus OC43 | … | 1 | … | 1 |
| hMPV | … | 1 | 1 | … |
| Coronavirus 229E | … | … | 1 | … |
| Parainfluenzavirus | … | … | … | 2 |
|
| 1 | 2 | … | 3 |
| RSV/influenzavirus A | 1 | … | … | … |
| hMPV | … | 1 | … | … |
| Parainfluenzavirus | … | … | … | 2 |
| Coronavirus OC43 | … | 1 | … | … |
| hMPV/adenovirus/influenzavirus B | … | … | … | 1 |
| Other bacteria and virus | … | … | 3 | 3 |
| Atypical microorganism and bacteria | 3 | 1 | 6 | 3 |
|
| ||||
|
| 2 | 1 | 5 | 2 |
|
| … | 1 | … | … |
|
| … | … | 1 | 2 |
|
| 1 | … | … | … |
|
| ||||
|
| … | … | … | 1 |
|
| … | … | … | 1 |
|
| 3 | 0 | 2 | 0 |
| Bacteria and atypical microorganism and virus | 4 | 2 | 3 | 0 |
| | 3 | … | 2 | … |
| Influenzavirus A | 1 | … | … | … |
| RSV | 1 | … | … | 1 |
| Parainfluenzavirus | 1 | … | … | … |
| Adenovirus/parainfluenzavirus | … | … | … | 1 |
|
| … | … | 2 | … |
| Influenzavirus B | … | … | 1 | … |
| Parainfluenzavirus and RSV | … | … | 1 | … |
|
| … | 1 | 1 | … |
| Influenzavirus A/coronavirus OC43 | 1 | … | … | … |
| RSV/parainfluenzavirus | … | 1 | … | … |
| RSV | … | … | 1 | … |
NOTE. hMPV, human metapneumovirus; NR-CAP, nonresponding community-acquired pneumonia; Rec-CAP, recurrent community-acquired pneumonia; RSV, respiratory syncytial virus.
Coinfections are mentioned for each bacterial pathogen.